Anteris Technologies Ltd (AVR)

Snapshot

AVR's Principal Activity is the the manufacturing and sale of proprietary ADAPT regenerative tissue products globally and continued research and development of regenerative medicine. Products under development in the aortic valve repair and replacement programme include DurAVRTM.

Announcements

Corporate Overview

Dividend History

DPS and Yield calculations use the Pay Date.

Ex-Date	Amount	Franking	Gross	Type	Payable
No dividends paid.

Show All

See Upcoming Dividends for all ASX companies.

Directors & Management

Name	Title	Since	Bio
Mr Stephen (Steve) Denaro	Company Secretary,Non-Executive Director	Oct 2018	Mr Stephen (Steve) Denaro Company Secretary,Non-Executive Director Mr Denaro has more than 30 years of senior level and Board level experience across publicly-listed companies, serving as Chief Financial Officer, Company Secretary and Director. He brings experience in managing compliance with finance and accounting regulatory requirements. He has had manage investment acquisitions and subsequent funding (domestic and international). Mr Denaro has a interest in start-up companies. He is also a Non-Executive Director and Chair of the Audit & Risk Committee of a not-for-profit company, National Affordable Housing Consortium Limited. He is Chair of the Risk Management Committee.
Dr Wenyi Gu	Non-Executive Director	Oct 2018	Dr Wenyi Gu Non-Executive Director Dr Gu currently works as a Research Fellow for the Australian Institute for Bioengineering and Nanotechnology at the University of Queensland where he began his postdoctoral work in 2001. Before engaging in nanomedicine, he worked on RNAibased gene therapy for years at Translational Research Institute. Dr Gu's research has been published in respected industry journals such as Nature Communications, Ad. Materials, ACS Nano and PNAS USA. He also held a Peter Doherty Fellowship (2006-2009) and was supported by the National Health and Medical Research Council to work at Harvard Medical School, Harvard University as a visiting fellow. He is a member of the Risk Management Committee.
Mr Wayne Paterson	Managing Director,Chief Executive Officer	Feb 2016	Mr Wayne Paterson Managing Director,Chief Executive Officer Mr Paterson has held range of senior positions in multinational pharmaceutical companies. Throughout his career, he has been in charge for building and managing businesses throughout the world, including; mergers, integrations, acquisitions and restructures as President and CEO. From 2005 to 2013 he held senior positions at Merck Kgaa, including President of Europe, Canada and Australia. Prior to this, Mr Paterson was President of markets, President of Japan and Global Head of Cardiovascular Medicine. Between 1999 and 2005, Mr Paterson served at Roche Pharmaceuticals where he was recently Head of Pharmaceuticals in Roche's South Korean operation. He also served as Head of Commercial Operations for Roche China based in Shanghai. He served as Non-Executive Director of Cepheid Inc from April 2015 to November 2016.
Mr John Seaberg	Non-Executive Director,Non-Executive Chairman	Oct 2014	Mr John Seaberg Non-Executive Director,Non-Executive Chairman Mr Seaberg has experience in cardiovascular products and markets. From 2008 until its sale to Baxter in 2012, Mr Seaberg served as Chairman of the Board of Synovis Inc. From 2007 until 2014 he was Founder, Chairman and CEO of NeoChord Inc. From 1996 to 2006, Mr Seaberg served at Guidant Corp where he served in range of executive level positions including Director of Bradycardia Marketing for Cardiac Rhythm Management, Vice President of Sales for Cardiac Surgery and Vice President of Sales for Cardiac Rhythm Management. In 1991, Mr Seaberg co-founded ACIST Medical and served as its first President and CEO. He was also the founder and CEO of Seaberg Medical. He is a member of the Risk Management Committee.
Matthew Mcdonnell	Chief Financial Officer	N/A
David St Denis	Chief Operating Officer	N/A
Martha Engel	General Counsel	N/A

Show All

Director Transactions

Date	Director	Type	Amount	Price	Value	Notes
07/06/21	Stephen (Steve) Denaro	Buy	+5,000	$8.009	$40,047	On-market trade
10/12/20	Wayne Paterson	Expiry	1,000	$3.80	$3,800	Options expired
10/12/20	John Seaberg	Expiry	1,000	$3.80	$3,800	Options expired
20/03/20	Stephen (Steve) Denaro	Issued	25,000	$3.50	$87,500	Issue of options
20/03/20	Wayne Paterson	Issued	350,000	$3.50	$1,225,000	Issue of options
20/03/20	John Seaberg	Issued	60,000	$3.50	$210,000	Issue of options
18/12/18	John Seaberg	Issued	700,000	$0.08	$56,000	Rights issue
18/12/18	Yanheng Wu	Issued	47,178,461	$0.08	$3,774,278	Rights issue
18/12/18	Lishan Zhang	Issued	62,897,248	$0.061	$3,836,732	Rights issue
18/12/18	Yanheng Wu	Issued	47,178,461	$0.061	$2,877,886	Rights issue
18/12/18	Lishan Zhang	Issued	62,897,248	$0.08	$5,031,781	Rights issue

Show All

Director Interests

Director	Last Notice	Direct Shares	Indirect Shares	Options	Convertibles
Stephen (Steve) Denaro	07/06/2021	0	5,000	25,000	N/A
Wayne Paterson	31/12/2020	9,167	N/A	403,248	N/A
John Seaberg	31/12/2020	8,858	N/A	67,000	N/A
Wenyi Gu	N/A	N/A	N/A	N/A	N/A

Show All

Top 20 Shareholders

About the Data

Name	Shares	Capital
HSBC Custody Nominees (Australia) Limited A/C 2	650,345	9.90%
National Nominees Limited <Db A/C>	374,479	5.70%
HSBC Custody Nominees (Australia) Limited Gsco Eca	288,924	4.40%
Mercer Street Global Opportunity Fund LLC	280,000	4.26%
BNP Paribas Nominees Pty Ltd <Ib Au Noms Retailclient Drp>	260,807	3.97%
Mr Patrick Chew	176,460	2.69%
Citicorp Nominees Pty Limited	161,115	2.45%
HSBC Custody Nominees (Australia) Limited	150,030	2.28%
CS Fourth Nominees Pty Limited <Hsbc Cust Nom Au Ltd 11 A/C>	129,285	1.97%
Mr Daniel Bernard Clough	89,583	1.36%
BNP Paribas Nominees Pty Ltd Six Sis Ltd <Drp A/C>	72,987	1.11%
Amedan Pty Ltd	65,340	0.99%
MDM Leby Hwang	59,000	0.90%
Through2 Investments Pty Ltd <Through2 Super Fund A/C>	48,000	0.73%
Sharepoint Solutions Pty Ltd	46,252	0.70%
J P Morgan Nominees Australia Pty Limited	45,476	0.69%
Mr Joseph John Doyle and Mrs Cheryl Anne Doyle	42,326	0.64%
Sean Barrett Pty Ltd <Super Fund A/C>	41,000	0.62%
Mr Donald Fletcher Cameron and Mrs Anne Cameron <Anne & Don Cameron S/F A/C>	40,000	0.61%
BNP Paribas Nominees Pty Ltd CIBC World Markets Inc <Drp>	30,459	0.46%

Show All

Shareholder Distribution

As reported in the most recent Annual Report.

Substantial Shareholders

Shareholders Buying

12 month transaction history compiled from ASX announcements.

Shareholders Selling

12 month transaction history compiled from ASX announcements.

Share Price History

Date	Close	Change	%Chg	Open	High	Low	Volume	Turnover

Full Month

Historical Data

Year	Closing Price	Last Trade
2020	$4.90	30 June

AVR Historical Price Data (CSV)

Up to 20 years of EOD share price history

Sign up to Download

You must be logged in to access this feature. Please sign up for free or login.